Tech Center 1600 • Art Units: 1656
This examiner grants 39% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18032105 | WW-DOMAIN-ACTIVATED EXTRACELLULAR VESICLES | Non-Final OA | President and Fellows of Harvard College |
| 17438088 | AMYLASES AND METHODS FOR MAKING AND USING THEM | Final Rejection | BASF SE |
| 17268130 | PROTEIN FRAGMENTATION CONTROL STRATEGY BY RE-OXIDATION IN DOWNSTREAM CHROMATOGRAPHY | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 17434832 | Precise Gene Activation Via Novel Designed Proteins Mediating Epigenetic Remodeling | Final Rejection | UNIVERSITY OF WASHINGTON |
| 18985413 | Culture conditions for high production of antibiotic compound aureothin from Streptomyces thioluteus | Non-Final OA | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18288401 | METHOD OF DETECTING BACTERIAL/FUNGAL CONTAMINATION | Non-Final OA | National University of Singapore |
| 17609841 | GENETICALLY MODIFIED MICROORGANISM FOR PRODUCING 3-HYDROXYHEXANEDIOIC ACID, (E)-HEX-2-ENEDIOIC ACID AND/OR HEXANEDIOIC ACID, AND PRODUCTION METHOD FOR SAID CHEMICALS | Non-Final OA | TORAY INDUSTRIES, INC. |
| 17268596 | METHOD FOR CONJUGATION OF BIOMOLECULES AND NEW USE OF GOLD DONOR FOR BIOMOLECULAR COMPLEX FORMATION | Non-Final OA | UNIWERSYTET JAGIELLONSKI |
| 17433767 | PROTEIN HYDROLYSATES WITH INCREASED YIELD OF N-TERMINAL AMINO ACID | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 17904189 | PRODUCTION OF GLYCOSYLATED PRODUCT IN HOST CELLS | Final Rejection | INBIOSE N.V. |
| 18674727 | LEUCONOSTOC HOLZAPFELII STRAIN FOR PREVENTING DEPILATION IMPROVING HAIR GROWTH OR IMPROVING SEXUAL DISFUNTION AND COMPOSITION COMPRISING THE SAME | Non-Final OA | COENBIO CO., LTD. |
| 17410482 | FEED INGREDIENT COMPRISING BUTYRATE AND A SELECTED FERMENTATION PRODUCT | Final Rejection | SUPERBREWED FOOD, INC. |
| 17958310 | PROBIOTIC AND FOLIC ACID COMPOSITIONS AND METHODS OF USING | Non-Final OA | Bonafide Health, LLC |
| 18287386 | REAGENT COMPOSITION AND KIT | Non-Final OA | DENKA COMPANY LIMITED |
| 17634909 | TEXTURING L. LACTIS WITH UNIQUE EPS GENE CLUSTERS | Non-Final OA | Chr. Hansen A/S |
| 16769964 | SPRAY-DRIED SIALYLLACTOSE | Non-Final OA | Chr. Hansen A/S |
| 17280125 | Protein Composition Production Method | Non-Final OA | Spiber Inc. |
| 18451748 | METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES | Non-Final OA | CAP DIAGNOSTICS, LLC, DBA PATHNOSTICS |
| 17830227 | METHODS AND SYSTEMS FOR PREPARING THERAPEUTIC SOLUTIONS FOR POLYMICROBIAL INFECTIONS | Final Rejection | CAP Diagnostics, LLC dba Pathnostics |
| 17440670 | NEW USES OF A MUTATED LACTONASE, AND COMPOSITIONS | Non-Final OA | AIX-MARSEILLE UNIVERSITE |
| 17415344 | ASPARAGINASE-INDUCED GLUTAMINE DEPLETION COMBINED WITH BCL-2 INHIBITION FOR TREATMENT OF HEMATOLOGIC AND SOLID CANCERS | Non-Final OA | UNIVERSITY OF MARYLAND, BALTIMORE |
| 17418505 | BIOSYNTHETIC METHODS AND SYSTEMS FOR PRODUCING MONOSACCHARIDES | Final Rejection | Cemvita Factory, Inc. |
| 18252354 | PREPARATION OF HIGHLY CONCENTRATED ALLERGENIC INTERMEDIATE | Non-Final OA | Jubilant HollisterStier LLC |
| 17431135 | ENZYMES WITH RUVC DOMAINS | Final Rejection | Metagenomi, Inc. |
| 17429374 | Methods for Diagnosing Alzheimer's Disease Based on Cell Growth Rate, Size and Protein Amount | Final Rejection | NeuroDiagnostics LLC |
| 17579559 | PARTICLE SEPARATOR SYSTEM, MATERIALS, AND METHODS OF USE | Non-Final OA | LEVITASBIO, INC. |
| 17828811 | METHOD FOR COUPLING ANTIBODY TO SURFACE OF CELL AND METHOD FOR APPLYING CELL COUPLED WITH THE ANTIBODY | Final Rejection | Xiamen Nuokangde Biological Technology Co., Ltd. |
| 17730850 | PROBIOTIC COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Schism Bioworks LLC |
| 17627488 | IMMOBILIZED ENZYME COMPOSITIONS FOR THE PRODUCTION OF HEXOSES | Final Rejection | BONUMOSE, INC. |
| 17541405 | CLASS 2 CRISPR-CAS RNA-GUIDED ENDONUCLEASES | Final Rejection | SCIENCE SOLUTIONS LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy